Wall Street brokerages forecast that pSivida Corp. (NASDAQ:PSDV) will post earnings per share of ($0.15) for the current quarter, Zacks reports. Two analysts have issued estimates for pSivida Corp.’s earnings. pSivida Corp. posted earnings of ($0.21) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 28.6%. The firm is expected to report its next quarterly earnings report on Monday, November 6th.

According to Zacks, analysts expect that pSivida Corp. will report full year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.63) to ($0.57). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover pSivida Corp..

pSivida Corp. (NASDAQ:PSDV) last released its quarterly earnings data on Monday, September 11th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.48 million. pSivida Corp. had a negative net margin of 245.19% and a negative return on equity of 134.34%.

A number of equities analysts have issued reports on the stock. HC Wainwright set a $8.00 price target on shares of pSivida Corp. and gave the stock a “buy” rating in a research report on Saturday, June 24th. Northland Securities set a $10.00 price target on shares of pSivida Corp. and gave the stock a “buy” rating in a research report on Wednesday, June 14th. FBR & Co reissued a “buy” rating on shares of pSivida Corp. in a research report on Wednesday, June 14th. Rodman & Renshaw assumed coverage on shares of pSivida Corp. in a research report on Tuesday, May 30th. They set a “buy” rating and a $8.00 price target for the company. Finally, Ladenburg Thalmann Financial Services set a $13.00 price target on shares of pSivida Corp. and gave the stock a “buy” rating in a research report on Wednesday, June 14th. Five investment analysts have rated the stock with a buy rating, pSivida Corp. currently has a consensus rating of “Buy” and an average price target of $8.60.

Shares of pSivida Corp. (NASDAQ PSDV) traded up 2.46% during mid-day trading on Friday, reaching $1.25. 599,849 shares of the company traded hands. The firm has a 50-day moving average price of $1.19 and a 200 day moving average price of $1.63. The firm’s market capitalization is $49.22 million. pSivida Corp. has a 52 week low of $1.03 and a 52 week high of $3.48.

An institutional investor recently bought a new position in pSivida Corp. stock. OxFORD Asset Management LLP purchased a new position in shares of pSivida Corp. (NASDAQ:PSDV) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned about 0.18% of pSivida Corp. at the end of the most recent quarter. 14.95% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “pSivida Corp. (PSDV) Expected to Announce Earnings of -$0.15 Per Share” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/24/psivida-corp-psdv-expected-to-announce-earnings-of-0-15-per-share.html.

pSivida Corp. Company Profile

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Get a free copy of the Zacks research report on pSivida Corp. (PSDV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related stocks with our FREE daily email newsletter.